CAJ | 학술논문

目的：探讨国产奥美沙坦酯治疗初发轻中度原发性高血压的有效性和安全性。方法选取初发轻中度原发性高血压患者116例，按照数字表法均分为2组（n=58）。实验组采用国产奥美沙坦酯治疗，对照组采用厄贝沙坦治疗，疗程均为24周。在治疗第2、4、6、8、12、16、20及24周时测量坐位平均收缩压、平均舒张压。在洗脱期末及疗程结束时对2组患者进行24 h动态血压监测，比较治疗前后血压、心率、心电图、肝肾功能、血糖、血脂等的变化、不良反应发生情况及T/P比值。结果治疗第2、4、6、8、12、16、20及24周时，坐位平均收缩压、平均舒张压均明显下降，差异有显著统计学意义（P<0.001）；实验组总有效率、MSSBP和MSDBP总体T/P比值略低于对照组，差异无统计学意义；实验组不良反应与对照组相当；肝肾功能等各项指标比较，差异无统计学意义。结论国产奥美沙坦酯治疗初发、轻中度原发性高血压安全、有效，不良反应较轻，值得临床推广应用。
목적：탐토국산오미사탄지치료초발경중도원발성고혈압적유효성화안전성。방법선취초발경중도원발성고혈압환자116례，안조수자표법균분위2조（n=58）。실험조채용국산오미사탄지치료，대조조채용액패사탄치료，료정균위24주。재치료제2、4、6、8、12、16、20급24주시측량좌위평균수축압、평균서장압。재세탈기말급료정결속시대2조환자진행24 h동태혈압감측，비교치료전후혈압、심솔、심전도、간신공능、혈당、혈지등적변화、불량반응발생정황급T/P비치。결과치료제2、4、6、8、12、16、20급24주시，좌위평균수축압、평균서장압균명현하강，차이유현저통계학의의（P<0.001）；실험조총유효솔、MSSBP화MSDBP총체T/P비치략저우대조조，차이무통계학의의；실험조불량반응여대조조상당；간신공능등각항지표비교，차이무통계학의의。결론국산오미사탄지치료초발、경중도원발성고혈압안전、유효，불량반응교경，치득림상추엄응용。
Objective To investigate the clinical effects and safety of olmesartan Medoxomil made in China in patients with mild and moderate hypertension.Methods 116 patients with mild and moderate primary hypertension were randomly divided into experimental group and control group. The experimental group were treated with olmesartan Medoxomil made in China for 24 weeks,while the control group with irbesartan for 24 weeks. If MSSBP≥140mmHg or MSDBP≥90mmHg after 4 weeks treatment, the dosage would be double till to 24 weeks treatment. All patients visited at 0,2nd,4t h,6th,8th,12th,16th,20th and 24th week respectively to measure MSDBP and MSSBP, At the end of placebo and course of treatment,24h ambulatory blood pressure monitoring (ABPM) was given to the patients in two groups. The change of MSSBP,MSDBP, heart rate,electrocardiogram and laboratory-related indexes before and after treatment as well as adverse reactions were compared, t/P ratio is so.Results At the time of 2nd,4th,6th,8th,12th,16th,20th and 24th week treatment, MSSBP, MSDBP levels in two groups were decreased obviously than the base line (P<0.001); The total effective rate and T/P ratio of experimental group were slightly lower than control group, but there was no significant difference. Incidence of adverse reaction and boratory-related indexes were no significant difference in two groups.Conclusion Olmesartan Medoxomil made in China treated mild and moderate primary hypertension is safety, effective, with milder adverse reactions.